Poxel

Poxel SA is a research-oriented pharmaceutical company dedicated to developing products for metabolic diseases, with a primary focus on type 2 diabetes. It offers Imeglimin, an orally active adjunct to diet and exercise that improves glycemic control in patients with type 2 diabetes. GLP-1 receptor agonists, which are incretin hormones that demonstrate glucose-dependent stimulation of insulin secretion and restore the normal characteristics of glucose-responsive insulin release; and AMP-activated protein kinase activators, enzymes that regulate systemic energy metabolism by modulating glucose and fatty acid homeostasis in various peripheral tissues such as skeletal muscle and liver. The company also provides Farnesoid X receptor agonists to induce a reduction in cholesterol synthesis and release in the liver; glucokinase activators that control glucose-induced β-cell insulin secretion and hepatic glucose metabolism by phosphorylating glucose in various key organs such as the liver, pancreas, intestine, and brain; and 11β-hydroxysteroid dehydrogenase type 1 inhibitors that modulate glucocorticoid levels in adipose tissue, skeletal muscle, and liver.